Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440013 | 0.80 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL9752077 | 0.77 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL8609740 | 0.74 | ALDH1A1 (0.34) | SMN1; SMN2 | |
| SCHEMBL5708446 | 0.74 | ALDH1A1 (0.34) | SMN1; SMN2 | |
| Butane SCHEMBL379581 | 0.70 | PTPN1 (0.40) | — | |
| SCHEMBL8053864 | 0.70 | PTPN1 (0.42) | — | |
| SCHEMBL5888021 | 0.70 | ATM (0.31) | — | |
| SCHEMBL3954537 | 0.70 | ALDH1A1 (0.30) | SMN1; SMN2 | |
| SCHEMBL5976 | 0.68 | TSHR (0.36) | — | |
| SCHEMBL2710911 | 0.67 | PTPN1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653295-B2 | Protease inhibitor; viricide | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-04-03 | — | — | US | disclosed |
| WO-2002048116-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| EP-1037905-A1 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| US-5962487-A | PICORNAVIRAL 3C PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999031122-A9 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMA (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999031122-A1 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | PRSS1, SERPINB1, SPINT2 | SMN1; SMN2 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.